The effects of goshajinkigan, a herbal medicine, on subjective symptoms and vibratory threshold in patients with diabetic neuropathy.

[1]  T. Onaya,et al.  The effect of prostaglandin E1.alpha CD on vibratory threshold determined with the SMV-5 vibrometer in patients with diabetic neuropathy. , 1994, Diabetes research and clinical practice.

[2]  N. Hotta,et al.  A Placebo‐controlled Double‐blind Study of Epalrestat (ONO‐2235) in Patients with Diabetic Neuropathy , 1993, Diabetic medicine : a journal of the British Diabetic Association.

[3]  Y. Ozaki,et al.  Anti-platelet action of isoliquiritigenin, an aldose reductase inhibitor in licorice. , 1992, European journal of pharmacology.

[4]  D. Owens,et al.  A Study of Peripheral Diabetic Neuropathy. The Application of Age‐Related Reference Values , 1991, Diabetic medicine : a journal of the British Diabetic Association.

[5]  H. Sasaki,et al.  Anti-platelet action of GU-7, a 3-arylcoumarin derivative, purified from glycyrrhizae radix. , 1990, Planta medica.

[6]  H. Sasaki,et al.  Isoliquiritigenin: a new aldose reductase inhibitor from glycyrrhizae radix. , 1990, Planta medica.

[7]  M. Nattrass,et al.  Variability of three standard neurophysiological techniques in established symptomatic diabetic polyneuropathy. , 1989, Diabetes research.

[8]  E. Bass,et al.  Measuring Diabetic Neuropathy: Assessment and Comparison of Clinical Examination and Quantitative Sensory Testing , 1989, Diabetes Care.

[9]  H. Sasaki,et al.  The existence of aldose reductase inhibitors in some kampo medicines (Oriental herb prescriptions). , 1989, Planta medica.

[10]  D. Greene,et al.  Are Disturbances of Sorbitol, Phosphoinositide, and Na+-K+-ATPase Regulation Involved in Pathogenesis of Diabetic Neuropathy? , 1988, Diabetes.

[11]  D. Greene,et al.  Pathogenesis and prevention of diabetic neuropathy. , 1988, Diabetes/metabolism reviews.

[12]  T. Onaya,et al.  Inhibition of aldose reductase activities by kampo medicines. , 1987, Planta medica.

[13]  J. Heimans,et al.  Reproducibility of vibratory perception thresholds in patients with diabetic neuropathy. , 1986, Diabetes research.

[14]  P. Dyck,et al.  Fiber loss is primary and multifocal in sural nerves in diabetic polyneuropathy , 1986, Annals of neurology.

[15]  Peter C Johnson,et al.  Pathogenesis of diabetic neuropathy , 1986, Annals of neurology.

[16]  A. Windebank,et al.  Capillary number and percentage closed in human diabetic sural nerve. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[17]  D. Greene,et al.  Action of Sorbinil in Diabetic Peripheral Nerve: Relationship of Polyol (Sorbitol) Pathway Inhibition to a myo-Inositol-mediated Defect in Sodium-Potassium ATPase Activity , 1984, Diabetes.

[18]  I. Steiness.  Vibratory perception in diabetics; a biothesiometric study. , 2009, Acta medica Scandinavica.